Search

Your search keyword '"Lampiris H"' showing total 36 results

Search Constraints

Start Over You searched for: Author "Lampiris H" Remove constraint Author: "Lampiris H"
36 results on '"Lampiris H"'

Search Results

4. Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study

5. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study

6. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

7. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy

8. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection

9. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation

11. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy.

12. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia.

13. Association between household exposure and cycle threshold in COVID-19 infected health care workers.

14. Cycle Threshold to Test Positivity in COVID-19 for Return to Work Clearance in Health Care Workers.

15. Evaluating the Concordance of Clinician Antiretroviral Prescribing Practices and HIV-ASSIST, an Online Clinical Decision Support Tool.

16. Opportunistic coinfection with Pneumocystis jirovecii and Coccidioides immitis associated with idelalisib treatment in a patient with chronic lymphocytic leukaemia.

18. HIV latency in isolated patient CD4 + T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing.

21. Geriatric Syndromes in Older HIV-Infected Adults.

22. The Montreal Cognitive Assessment: A Pilot Study of a Brief Screening Tool for Mild and Moderate Cognitive Impairment in HIV-Positive Veterans.

23. Modification of the Abbott RealTime assay for detection of HIV-1 plasma RNA viral loads less than one copy per milliliter.

24. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response.

25. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.

26. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy.

27. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy.

28. Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy.

29. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial.

30. Resolution of hepatitis C virus-induced steatosis improves tolerability of antiretroviral drugs associated with hepatotoxicity in an HIV-infected individual.

31. Covering all the bases: targeting HIV-1 integrase.

32. The independent effect of drug resistance on T cell activation in HIV infection.

33. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy.

34. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study.

35. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.

36. Streptococcus pneumoniae transmission in chronic-care facilities: description of an outbreak and review of management strategies.

Catalog

Books, media, physical & digital resources